Operating cash flow exceeded net income in every reported quarter (OCF/NI as high as 2.41x) and FCF margin recovered to 24.9% in 2026Q3, though capex at 3.9% of revenue runs roughly half of the ~$600M quarterly D&A.
Danaher Corporation (DHR) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 6.86B | 6.42B | 6.69B | 7.16B | 8.52B | 8.36B | 6.21B | 3.95B | 4.02B | 3.48B | 3.52B | 3.8B | 3.76B | 3.59B | 3.42B | 2.63B | 2.08B | 1.8B | 1.86B | 1.65B | 1.55B | 1.2B | 1.03B | 861.54M | 710.35M | 608.47M | 512.25M | 419.1M | 331.3M | 278.4M | 217.1M |
| Operating CF Margin % | - | 26.12% | 28.01% | 29.99% | 31.97% | 28.38% | 27.86% | 22.06% | 23.59% | 18.97% | 20.86% | 26.34% | 18.87% | 18.75% | 18.7% | 16.32% | 15.79% | 16.1% | 14.64% | 14.93% | 16.12% | 15.08% | 15% | 16.27% | 15.52% | 16.09% | 13.56% | 13.11% | 11.38% | 13.57% | 11.98% |
| Operating CF Growth % | 34.75% | -4.07% | -6.64% | -15.91% | 1.93% | 34.63% | 57.1% | -1.75% | 15.65% | -1.25% | -7.36% | 1.15% | 4.83% | 4.99% | 30.03% | 26% | 15.74% | -3.13% | 12.96% | 6.37% | 28.53% | 16.51% | 19.93% | 21.28% | 16.74% | 18.79% | 22.23% | 26.5% | 19% | 28.24% | 24.63% |
| Net Income | 4.33B | 3.61B | 3.9B | 4.22B | 7.21B | 6.35B | 3.65B | 2.43B | 2.65B | 2.47B | 2.15B | 2.6B | 2.6B | 2.69B | 2.3B | 1.94B | 1.79B | 1.15B | 1.32B | 1.37B | 1.12B | 897.8M | 746M | 536.83M | 290.39M | 297.67M | 324.21M | 261.6M | 182.9M | 154.8M | 207.8M |
| Depreciation & Amortization | 1.91B | 2.45B | 2.35B | 2.17B | 2.13B | 2.17B | 1.77B | 1.19B | 1.18B | 1.24B | 1.13B | 1.05B | 938.5M | 895M | 839.8M | 634.93M | 397.08M | 341.59M | 339.29M | 268.49M | 217.19M | 176.97M | 156.13M | 133.44M | 129.56M | 178.39M | 149.72M | 126.4M | 108.7M | 76.1M | 68.6M |
| Stock-Based Compensation | 297M | 298M | 288M | 306M | 295M | 184M | 187M | 158.8M | 151.4M | 139.4M | 129.8M | 139M | 121.1M | 117.7M | 109.9M | 95.6M | 88.12M | 87.35M | 86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -440M | -440M | 0 | 0 | -559M | -318M | -462M | -415.2M | -195.1M | -426.9M | -383.9M | -151.3M | 177.3M | 254.6M | 184.9M | 271.39B | 0 | 0 | -27.69M | 29.87M | 24.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 991M | 1.21B | -117M | 864M | 961M | 601M | 457M | 709.4M | 326.9M | 410.2M | 773.6M | 112.7M | -333.8M | -619.3M | -297.4M | -271.52B | -313.81M | -84.75M | 27.69M | -136.09M | 67.19M | 0 | 0 | 0 | 143.75M | 0 | 0 | 0 | 37.4M | 59.4M | -96.8M |
| Working Capital Changes | -229M | -710M | 266M | -393M | -1.52B | -658M | 605M | -123.2M | -90.1M | -353M | -279.2M | 51.4M | 256.9M | 242.3M | 278.5M | 84.63M | 119.95M | 304.94M | 116.11M | 113.6M | 116.69M | 129.03M | 131.09M | 191.27M | 146.64M | 132.42M | 38.31M | 31.1M | 2.3M | -11.9M | 37.5M |
| Change in Receivables | -174M | -216M | 331M | 322M | -477M | -611M | -264M | -156.4M | -58.3M | -161.4M | -183.1M | -52.1M | -142.2M | -48.7M | -79.7M | -135.28M | -262.12M | 106.13M | 71.4M | 0 | 0 | 0 | 0 | 0 | 59.03M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -45M | -58M | 147M | 185M | -486M | -502M | -123M | -21.9M | -143.3M | -27.4M | 9.4M | 119.7M | 50.6M | 62.9M | 69.8M | 162.02M | -166.45M | 211.59M | 33.12M | 38.09M | 3.37M | -22.48M | 65.53M | 21.06M | 77.54M | 66.83M | -38.45M | 11.1M | 12.5M | 14.7M | 38.9M |
| Change in Payables | -17M | 9M | 19M | -149M | 5M | 549M | 227M | 18.1M | 225.8M | -54.4M | 78.1M | 103.9M | 118.4M | 182.6M | 57M | 36.6M | 224.71M | -89.85M | 3.71M | 0 | 0 | 0 | 0 | 0 | 54.01M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -11.08B | -1.2B | -1.98B | -7.08B | -2.23B | -12.99B | -21.24B | -1.24B | -2.95B | -843.4M | -5.24B | -14.95B | -3.44B | -552.5M | -1.89B | -5.85B | -2.29B | -942.94M | -567.4M | -3.45B | -2.77B | -965.41M | -1.63B | -368.05M | -1.14B | -487.57M | -795.3M | -153.7M | -599.7M | -210M | -142.7M |
| Capital Expenditures | -1.13B | -1.16B | -1.39B | -1.38B | -1.15B | -1.29B | -791M | -635.5M | -584M | -570.7M | -589.6M | -512.9M | -465.4M | -538.1M | -458.3M | -334.47M | -217.33M | -188.55M | -193.78M | -162.07M | -137.71M | -121.21M | -115.91M | -80.34M | -65.43M | -80.58M | -88.5M | -153.7M | -616M | -62.8M | -51.3M |
| CapEx % of Revenue | 4.42% | 4.71% | 5.83% | 5.79% | 4.32% | 4.39% | 3.55% | 3.55% | 3.43% | 3.11% | 3.49% | 3.55% | 2.34% | 2.81% | 2.51% | 2.08% | 1.65% | 1.69% | 1.53% | 1.47% | 1.44% | 1.52% | 1.68% | 1.52% | 1.43% | 2.13% | 2.34% | 4.81% | 21.17% | 3.06% | 2.83% |
| Acquisitions | -9.84B | 9M | -558M | -5.61B | -637M | -10.94B | -20.14B | -331.3M | -2.17B | -385.8M | -4.88B | -14.3B | -3.13B | -249.8M | -1.8B | -6.2B | -2.07B | -703.51M | -423.21M | -3.58B | -2.66B | -885.08M | -1.59B | -312.28M | -1.16B | -406.99M | -706.79M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -191M | 66M | 47M | 23M | 60M | 50M | 26M | 28.9M | -65M | -272.7M | -4.65B | -89M | -2.98B | -14.4M | 367.5M | 683.28M | 1.56M | 15.88M | 1.09M | 14.81M | -74.11M | 40.88M | 30.89M | 24.57M | 79.03M | 0 | 0 | 0 | 16.3M | -147.2M | -91.4M |
| Cash from Financing | 8.32B | -2.96B | -8.38B | -273M | -2.57B | 1.29B | 1.01B | 16.37B | -797M | -3.1B | 2.04B | 9.05B | -218.2M | -1.61B | -388.4M | 2.09B | 116.8M | 407.23M | -1.12B | 1.71B | 1.22B | -511.56M | -38.05M | -110.34M | 516.3M | 409.71M | 200.48M | -51.8M | 238.3M | -61.3M | -56.1M |
| Debt Issued (Net) | 8.31B | 1.04B | -1.67B | -1.63B | -1.69B | 1.97B | -1.9B | 13.35B | -442M | -2.66B | 2.79B | 9.16B | -414.7M | -967.8M | 134.4M | 1.04B | -9.4M | 274.72M | -1.09B | 1.13B | 1.15B | -292.24M | -66.28M | -145.51M | 17.71M | 410.52M | 266.09M | -129.9M | 214.9M | -10.8M | -55.4M |
| Equity Issued (Net) | -930M | -3B | -5.82B | 68M | 31M | 86M | 3.55B | 3.82B | 96M | 68.8M | 164.5M | 249M | 0 | 177.4M | -436.4M | 1.11B | 178.4M | 174.23M | 8.27M | 615.54M | 98.42M | -197.76M | 45.96M | 50.5M | 512.11M | 10.87M | -55.59M | 87.9M | 28.4M | -71.1M | -3.2M |
| Dividends Paid | -1.02B | -878M | -768M | -821M | -818M | -742M | -615M | -526.7M | -433.4M | -378.3M | -399.8M | -354.1M | -227.7M | -52.1M | -86.4M | -61.32M | -52.21M | -41.72M | -38.26M | -34.27M | -24.59M | -21.55M | -17.73M | -15.33M | -13.52M | -11.68M | -10.02M | -9.9M | -10.5M | -5.9M | -5.1M |
| Share Repurchases | -919M | -3.09B | -5.98B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -648.4M | 0 | 0 | 0 | -74.17M | -117.49M | 0 | -257.7M | 0 | 0 | 0 | -17.3M | -82.17M | 0 | -2.1M | -80.2M | -12.1M |
| Other Financing | 1.96B | -125M | -131M | 2.11B | -95M | -16M | -29M | -274.7M | -17.6M | -124.2M | -512.3M | -3.3M | 424.2M | -763.3M | 0 | 2.09T | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.33M | 0 | 0 | 0 | 100K | 7.8M | -8.7M | -6.1M |
| Net Change in Cash | 4.16B | 2.54B | -3.79B | -131M | 3.41B | -3.45B | -13.88B | 19.12B | 157.7M | -333.4M | 172.9M | -2.21B | -109.6M | 1.44B | 1.14B | -1.1B | -88.94M | 1.33B | 153.75M | -78.7M | 2.26M | -293.56M | -621.04M | 419.69M | 103.9M | 529.63M | -83.36M | 212.5M | -28.9M | 6.9M | 18.4M |
| Free Cash Flow | 5.73B | 5.26B | 5.3B | 5.78B | 7.37B | 7.06B | 5.42B | 3.32B | 3.44B | 2.91B | 2.93B | 3.29B | 3.29B | 3.05B | 2.96B | 2.29B | 1.87B | 1.61B | 1.67B | 1.48B | 1.41B | 1.08B | 917.31M | 781.2M | 644.92M | 527.89M | 423.74M | 265.4M | -284.7M | 215.6M | 165.8M |
| FCF Margin % | 22.36% | 21.41% | 22.18% | 24.2% | 27.65% | 23.98% | 24.31% | 18.51% | 20.17% | 15.86% | 17.37% | 22.79% | 16.54% | 15.94% | 16.19% | 14.24% | 14.14% | 14.41% | 13.11% | 13.46% | 14.69% | 13.56% | 13.31% | 14.76% | 14.09% | 13.96% | 11.22% | 8.3% | -9.78% | 10.51% | 9.15% |
| FCF Growth % | 14.15% | -0.68% | -8.39% | -21.53% | 4.29% | 30.4% | 63.35% | -3.55% | 18.26% | -0.86% | -10.85% | -0.12% | 8.07% | 3.06% | 29.01% | 22.75% | 15.8% | -3.18% | 12.24% | 5.26% | 30.2% | 18.02% | 17.42% | 21.13% | 22.17% | 24.58% | 59.66% | 193.22% | -232.05% | 30.04% | 44.17% |
| FCF per Share | 8.10 | 7.40 | 7.18 | 7.78 | 9.99 | 9.59 | 7.54 | 4.57 | 4.84 | 4.12 | 4.19 | 4.64 | 4.60 | 4.29 | 4.15 | 3.27 | 2.73 | 2.40 | 2.48 | 2.25 | 2.17 | 1.65 | 1.40 | 1.21 | 1.02 | 0.87 | 0.73 | 0.45 | -0.49 | 0.37 | 0.30 |
| FCF Conversion (FCF/Net Income) | 1.32x | 1.78x | 1.72x | 1.50x | 1.18x | 1.30x | 1.70x | 1.55x | 1.52x | 1.40x | 1.38x | 1.46x | 1.45x | 1.33x | 1.49x | 1.33x | 1.16x | 1.56x | 1.41x | 1.35x | 1.38x | 1.34x | 1.39x | 1.60x | 2.45x | 2.04x | 1.58x | 1.60x | 1.81x | 1.80x | 1.04x |
| Interest Paid | -95M | 331M | 370M | 0 | 347M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | -267M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DHR stock.
Danaher Corporation (DHR) generated $6.42B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Danaher Corporation (DHR) generated $5.26B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Danaher Corporation (DHR) spent $1.16B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Danaher Corporation (DHR) returned $878.0M to shareholders via cash dividends and spent $3.09B on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Acquisition outflows outpacing FCF
Metrics are mathematically derived from official filings.
Earnings Consistently Convert to Cash
Operating cash flow exceeded net income in all ten reported quarters, with the OCF/NI ratio ranging from 1.28x to 2.41x; cumulatively, Danaher generated roughly $16.0B of operating cash against approximately $9.5B of GAAP net income, per its quarterly filings.
The persistent gap is largely structural rather than opportunistic: quarterly depreciation and amortization held steady between $580M and $659M, dwarfing the $57M-$146M of stock-based compensation, so non-cash add-backs alone plausibly explain most of the delta. This suggests reported earnings are a conservative proxy for economic performance, though the 2.41x print in 2025Q2 — a quarter where net income troughed at $555M — shows the ratio can be mechanically inflated when the denominator is depressed by non-operating charges, so the trend matters more than any single quarter.
Free Cash Flow Margins Reaccelerate
Danaher's free cash flow margin recovered from an 18.2% trough in 2026Q1 to 24.9% in 2026Q3, generating approximately $1.6B of FCF in the latest quarter and cumulatively about $13.1B over the ten-quarter window on a reported basis.
The trajectory mirrors the income statement's post-destocking recovery: FCF margins of 18.4% in both 2025Q1 and 2025Q2 gave way to 22.6%-25.5% in the second half of 2025 before a Q1 seasonal dip, indicating the bioprocessing inventory rebalancing weighed on cash generation as well as revenue. At 24.9%, Danaher's current FCF margin sits materially above Thermo Fisher's 16.0% and Agilent's 19.5%, which may support the premium multiple, but investors should note the latest print also benefited from a $306M working capital draw that may not repeat.
Capital Intensity Falls Below Depreciation
Capital expenditure as a share of revenue declined from 7.9% in 2024Q4 to 3.9% in 2026Q3, while quarterly depreciation and amortization of roughly $600M ran about 2x capex, implying the company is currently spending well below asset replacement levels.
A capex-to-D&A ratio persistently below 1.0x ($237M-$371M of quarterly capex against $580M-$659M of D&A) reads as a genuinely asset-light consumables model, but it also raises the question of whether growth investment is being deferred amid weak biotech funding. The elevated 7.9% ratio in 2024Q4 likely reflects a one-time build-out rather than a structural shift, and if the recent 3.9%-4.3% range persists while revenue accelerates, operating leverage should improve — unless it signals underinvestment that surfaces as capacity constraints later.
Acquisitions Absorb Multiple Years of FCF
Danaher deployed approximately $9.8B net toward acquisitions in 2026Q2 and $4.5B in 2024Q2, alongside roughly $10.0B of cumulative buybacks and steadily rising dividends from $194M to $281M per quarter, per cash flow statement disclosures.
The pattern shows a clear hierarchy: dividends are the only consistently growing commitment, while buybacks are lumpy and strategically scaled back (from $4.5B in 2024Q2 to zero in the last three quarters) to fund M&A. A single quarter's $9.8B acquisition outflow exceeded two full years of that period's cumulative free cash flow, which implies either meaningful incremental borrowing or a substantial draw on the cash balance — either way, the balance sheet absorbed a step-change in 2026Q2 that warrants monitoring for leverage normalization.
What the Cash Flow Statement Obscures
Reported FCF of $1.6B in 2026Q3 excludes the full cash cost of stock-based compensation, which ran $57M-$146M in prior quarters, and the period's working capital release of $306M, meaning underlying discretionary cash generation was likely closer to $1.2B-$1.3B.
Additionally, the zero values shown for SBC and depreciation in 2026Q3 and the blank acquisition line should be treated as data unavailable rather than as genuine zeros, so the latest quarter's quality of cash cannot be fully reconciled from this dataset. More broadly, FCF as presented does not capture the deferred maintenance implied by capex at roughly half of D&A, nor the integration cash costs associated with the Abcam purchase; investors should also weigh that the bioprocessing destocking tailwind now reversing may have temporarily flattered receivables, making the recent conversion advantage less durable than the headline ratios suggest.